World Journal of Gastrointestinal Oncology最新文献

{"title":"Lipid levels and insulin resistance markers in patients with colorectal cancer: Propensity score matching analysis.","authors":"Ren-Hao Hu, Dong-Yi Yan, Ke-Hui Zhang, Di Zhang, Xi-Mao Cui, Xiao-Hua Jiang, Shun Zhang","doi":"10.4251/wjgo.v17.i1.100204","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.100204","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is a prevalent malignant neoplasm characterized by subtle early manifestations.</p><p><strong>Aim: </strong>To investigate the correlation among serum lipid profiles, the triglyceride-glucose (TyG) index, and the atherosclerotic index (AI) in patients with CRC. Furthermore, it explored the clinical diagnostic utility of combining serum lipids with cancer antigens in the context of CRC.</p><p><strong>Methods: </strong>A retrospective analysis encompassed 277 patients with CRC and 1034 healthy individuals.</p><p><strong>Results: </strong>Following propensity score matching, patients with CRC exhibited significantly reduced levels of serum triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol (LDL-C), as well as a diminished TyG index. Conversely, they displayed elevated AI levels compared to their healthy counterparts. Patients in advanced stages exhibited lower serum levels of TG, TC, and LDL-C compared to those in early stages. Patients with positive lymph node metastasis demonstrated reduced levels of TG, LDL-C, and the TyG index. Receiver operating characteristic analysis revealed that the combination of the TyG index, carcinoembryonic antigen, and carbohydrate antigen 19-9 yielded the highest positive prediction rate for CRC at 75.3%.</p><p><strong>Conclusion: </strong>Preoperative serum lipid profiles exhibit a robust association with patients with CRC. The concurrent assessment of multiple serum lipids and cancer antigens effectively enhances the diagnostic accuracy for CRC.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"100204"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TRIPLET combined with microwave ablation: A novel treatment for advanced hepatocellular carcinoma.","authors":"Fei-Yu Zhao, Guo-Wei Si, Nian-Song Qian","doi":"10.4251/wjgo.v17.i1.98572","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i1.98572","url":null,"abstract":"<p><p>This editorial comments on a study by Zuo <i>et al</i>. The focus is on the efficacy of hepatic arterial infusion chemotherapy combined with camrelizumab and apatinib (the TRIPLET regimen), alongside microwave ablation therapy, in treating advanced hepatocellular carcinoma (HCC). The potential application of this combination therapy for patients with advanced HCC is evaluated.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 1","pages":"98572"},"PeriodicalIF":2.5,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis of radiotherapy for esophageal cancer in elderly patients exceeding seventy-five years old.","authors":"Li-Li Hu, Feng Rong, Lei Liu, Ling Zhang, Lei-Lei Zhang, Qun Yang, Zhao-Long Xia, Hui Wang","doi":"10.4251/wjgo.v16.i12.4636","DOIUrl":"10.4251/wjgo.v16.i12.4636","url":null,"abstract":"<p><strong>Background: </strong>Esophageal cancer (EC) often occurs in the elderly, with approximately 33% of patients aged ≥ 75 years at the time of diagnosis.</p><p><strong>Aim: </strong>To evaluate the prognostic factors for radiotherapy (RT) in elderly patients with unresectable EC.</p><p><strong>Methods: </strong>We retrospectively analyzed the clinical characteristics, toxic reactions, and survival information of EC patients aged ≥ 75 years who underwent intensity-modulated RT at Lu'an Hospital of Anhui Medical University between January 2016 and September 2023. Kaplan-Meier analysis was used to draw the overall survival (OS) curves, and Cox regression analysis was employed to evaluate the influence of various clinical factors on the prognosis.</p><p><strong>Results: </strong>A total of 139 patients were enrolled. The median follow-up time was 52.0 months. The median OS was 20.0 months. The 1-year, 2-year, 3-year, and 5-year OS rates were 69.8%, 38.7%, 28.2%, and 17.5%, respectively. Univariate analysis showed that age, radiation dose, and chemotherapy had no significant impact on prognosis. Multivariate analysis indicated that clinical stage [III-IVa <i>vs</i> I-II, hazard ratio (HR) = 2.421, 95% confidence interval (CI): 1.242-4.718, <i>P</i> = 0.009; IVb <i>vs</i> I-II, HR = 4.222, 95%CI: 1.888-9.438, <i>P</i> < 0.001), Charlson comorbidity index (CCI) (0 <i>vs</i> ≥ 1, HR = 1.539, 95%CI: 1.015-2.332, <i>P</i> = 0.042), and nutritional risk screening 2002 (NRS2002) (< 3 <i>vs</i> ≥ 3, HR = 2.491, 95%CI: 1.601-3.875, <i>P</i> < 0.001) were independent prognostic factors for OS.</p><p><strong>Conclusion: </strong>Our results suggest that CCI and NRS2002 were independent prognostic factors of OS for unresectable elderly EC patients undergoing RT. For elderly patients with EC, full attention should be given to biological age-related indicators, such as comorbidities and nutrition, when formulating treatment protocols. These factors should be considered in future clinical practice.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"16 12","pages":"4636-4649"},"PeriodicalIF":2.5,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of transhepatic arterial chemoembolization with drug-loaded microspheres in unresectable primary liver cancer.","authors":"Jun Deng, Yan-Hong Mi, Le Xie, Xiong-Xing Sun, Dan-Hong Liu, Hua-Jun Long, Li-Yong He, Da-Hua Wu, Hong-Cai Shang","doi":"10.4251/wjgo.v16.i12.4728","DOIUrl":"10.4251/wjgo.v16.i12.4728","url":null,"abstract":"<p><strong>Background: </strong>Transhepatic arterial chemoembolization (TACE), as a local treatment, has been widely used in the treatment of unresectable liver cancer. The introduction of drug carrier microspheres has brought new hope for the therapeutic effect of TACE. Microspheres can realize the slow release and directional delivery of drugs, reduce systemic toxicity and improve local curative effect.</p><p><strong>Aim: </strong>To compare the effectiveness of traditional transcatheter arterial chemoembolization against microsphere-assisted transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma that is incurable.</p><p><strong>Methods: </strong>We searched the PubMed, Embase, Cochrane Library, and CNKI databases for clinical trials of drug-luting beads TACE (DEB-TACE) <i>vs</i> conventional TACE (cTACE) for the treatment of unresectable liver cancer. We screened references based on inclusion and exclusion criteria and then selected valid data for meta-analysis using RevMan 53 software. The complete response (CR) rate, partial response (PR) rate, postoperative stable disease (SD) rate, and 6-month and 12-month survival rates were compared.</p><p><strong>Results: </strong>A total of 12 articles were included, including 1177 patients, 519 of whom received DEB-TACE and 658 of whom received cTACE. The CR rate in the DEB-TACE group was much greater than that in the cTACE group [relative risk (RR) = 1.42, 95%CI: 1.18-1.72, <i>P</i> = 0.0002]. The 12-month survival rate significantly increased (RR = 1.09; 95%CI: 1.01- 1.17, <i>P</i> = 0.03); the PR rate (RR = 1.13; 95%CI: 0.97-1.30, <i>P</i> = 0.12); the SD rate (RR = 0.82; 95%CI: 0.64-1.05, <i>P</i> = 0.12); and the 6-month survival rate (RR = 1.05; 95%CI: 1.00-1.10, <i>P</i> = 0.07). There was no significant difference (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>Compared with those of iodized oil TACE, the drug-loaded microspheres tended to have therapeutic advantages.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"16 12","pages":"4728-4737"},"PeriodicalIF":2.5,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142830032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing hepatocellular carcinoma treatment with hepatic arterial infusion chemotherapy.","authors":"Eda Caliskan Yildirim, Yakup Ergun","doi":"10.4251/wjgo.v16.i12.4757","DOIUrl":"10.4251/wjgo.v16.i12.4757","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) remains a major challenge in oncology, being a leading cause of cancer-related mortality worldwide. Early-stage HCC is typically treated with surgical resection, transplantation, or ablation, while advanced-stage HCC relies on systemic therapies like sorafenib and newer combinations such as atezolizumab-bevacizumab. Despite these advancements, there is still a need for effective treatments for unresectable HCC, especially in cases with macroscopic vascular invasion. Hepatic arterial infusion chemotherapy (HAIC) has demonstrated promising outcomes in Asia for the treatment of unresectable HCC, yet its application in Western countries has been relatively limited. This letter reviews the recent meta-analysis by Zhou <i>et al</i> published in the <i>World Journal of Gastrointestinal Oncology</i>, which demonstrates the efficacy and safety of HAIC <i>vs</i> sorafenib. The analysis includes 9 randomized controlled trials and 35 cohort studies, highlighting significant improvements in overall survival, progression-free survival, and objective response rates with HAIC and its combinations. The editorial explores the reasons behind the limited use of HAIC in Western countries. It underscores the potential of HAIC to enhance treatment outcomes for advanced HCC and calls for more research and broader adoption of HAIC in clinical practice globally.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"16 12","pages":"4757-4761"},"PeriodicalIF":2.5,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577366/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142830061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Matrine promotes colorectal cancer apoptosis by downregulating shank-associated RH domain interactor expression.","authors":"Yuan-Chen Zhou, Qian-Qian Wang, Ge-Yu-Jia Zhou, Teng-Fei Yin, Dong-Yan Zhao, Xi-Zhen Sun, Chang Tan, Lei Zhou, Shu-Kun Yao","doi":"10.4251/wjgo.v16.i12.4700","DOIUrl":"10.4251/wjgo.v16.i12.4700","url":null,"abstract":"<p><strong>Background: </strong>The 5-year survival rate of patients with colorectal cancer (CRC) in China is only 56.9%, highlighting the need for new therapeutic drugs. Previous studies have shown that matrine exhibits antitumor effects by inducing apoptosis. However, the mechanism by which matrine regulates antiapoptotic proteins in CRC remains unclear.</p><p><strong>Aim: </strong>To identify apoptotic proteins from proteomics and investigate the role of matrine in impeding CRC apoptosis by regulating these proteins.</p><p><strong>Methods: </strong>Tumor and adjacent normal tissues were collected from 52 patients with CRC who underwent surgery between January and December 2021. Data-independent acquisition quantitative proteomic analysis was performed to identify differentially expressed apoptotic proteins. The selected apoptotic proteins were identified through their association with tumor-node-metastasis (TNM) stage and prognosis, then confirmed by immunohistochemical (IHC) staining in validation cohort. <i>In vitro</i>, the role of matrine or apoptotic proteins on cancer cells were analyzed.</p><p><strong>Results: </strong>Compared to normal tissues, 88 anti-apoptotic proteins from proteomic results were selected. Among them, Shank-associated RH domain interactor (SHARPIN) was identified because of its relationship with TNM stage and overall survival in TCGA database. In the IHC-confirmed cohort, SHARPIN was highly expressed in CRC tissues and localized in the cytoplasm. Higher SHARPIN expression was associated with TNM stage, carbohydrate antigen 153 levels, and gross type compared to low expression. SHARPIN knockdown promoted apoptosis, significantly upregulated the expression of Bcl-2 associated agonist of cell death, Bcl-2 associated X protein, caspase 3, and caspase 8, and downregulated B-cell lymphoma-2 (<i>P</i> < 0.05). Importantly, matrine treatment promoted apoptosis and reversed the proliferation, invasion, and migration of CRC cells by repressing SHARPIN.</p><p><strong>Conclusion: </strong>SHARPIN was identified as an upregulated anti-apoptotic protein in CRC, and matrine exhibited anticancer effects by downregulating its expression. Thus, matrine appears to be a promising drug for CRC.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"16 12","pages":"4700-4715"},"PeriodicalIF":2.5,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577358/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142830095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mixed pancreatic ductal adenocarcinoma and well-differentiated neuroendocrine tumor: A case report.","authors":"Xiaofeng Zhao, Tina Bocker Edmonston, Ronald Miick, Upasana Joneja","doi":"10.4251/wjgo.v16.i12.4738","DOIUrl":"10.4251/wjgo.v16.i12.4738","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) are rare malignancies affecting the pancreas. The World Health Organization defines MiNENs as neoplasms composed of morphologically recognizable neuroendocrine and non-neuroendocrine components, each constituting 30% or more of the tumor volume. Adenocarcinoma-neuroendocrine carcinoma is the most frequent MiNEN combination. A well-differentiated neuroendocrine tumor (NET) component is rarely reported in MiNENs.</p><p><strong>Case summary: </strong>Here we report a rare case with intermingled components of ductal adenocarcinoma and grade 1 well-differentiated NET in the pancreas. The two tumors show distinct histology and significant differentiation discrepancy (poorly differentiated high grade adenocarcinoma and well-differentiated low grade NET), and also present as metastases in separate lymph nodes. Next generation sequencing of the two components demonstrates <i>KRAS</i> and <i>TP53</i> mutations in the ductal adenocarcinoma, but no genetic alterations in the NET, suggesting divergent origins for these two components. Although tumors like this meet the diagnostic criteria for MiNEN, clinicians often find the diagnosis and staging confusing and impractical for clinical management.</p><p><strong>Conclusion: </strong>Mixed NET/non-NET tumors with distinct histology and molecular profiles might be better classified as collision tumors rather than MiNENs.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"16 12","pages":"4738-4745"},"PeriodicalIF":2.5,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center.","authors":"Wagner Eduardo Cruz-Diaz, Victor Paitan, Jersinho Medina, Raymundo Flores, Juan Haro-Varas, Raul Mantilla, Victor Castro-Oliden","doi":"10.4251/wjgo.v16.i12.4675","DOIUrl":"10.4251/wjgo.v16.i12.4675","url":null,"abstract":"<p><strong>Background: </strong>Numerous studies have indicated that the temozolomide and capecitabine regimen (TEMCAP) exhibits a certain level of efficacy in treating advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET). However, published data from Peru are limited. We hypothesize that this regimen could be a viable therapeutic option for advanced GEP-NET in the Peruvian population.</p><p><strong>Aim: </strong>To evaluate overall survival (OS) in patients diagnosed with advanced GEP-NET treated with TEMCAP at the Instituto Nacional de Enfermedades Neoplásicas (INEN) in Lima-Perú.</p><p><strong>Methods: </strong>A retrospective review was conducted to identify patients with GEP-NEN treated with the TEMCAP regimen between 2011 and 2021 at the INEN. A total of thirty-eight patients were included in the final analysis: Thirty-five received TEMCAP as a first-line treatment, and three as a second-line treatment. The primary objective was to evaluate OS. The efficacy and safety of TEMCAP were assessed until the occurrence of unacceptable toxicity or disease progression. Survival outcomes were estimated using the Kaplan-Meier method.</p><p><strong>Results: </strong>The median age of the patients was 52 years (range 24-77 years), and 53.3% were female. The most common symptoms at diagnosis were abdominal pain in 31 patients (81.6%). Primary tumors included 12 in the rectum (31.6%), 11 in the pancreas (28.9%), 3 in the ileum (7.9%), 2 in the mesentery (5.3%), 2 in the small intestine (5.3%), 1 in the appendix (2.6%), 1 in the stomach (2.6%) and 6 cases of liver metastasis of unknown primary (15.8%). Five were neuroendocrine tumors (NET) G1 (13.2%), 33 were NET G2 (86.8%), five had Ki67 < 3% (13.2%), and 33 had Ki67 between 3% and 20% (86.8%). TEMCAP was administered to 35 (92.1%) patients as first-line treatment. OS at 12, 36, and 60 months was estimated in 80%, 66%, and 42%, respectively, with a median OS of 49 months.</p><p><strong>Conclusion: </strong>TEMCAP therapy is a viable first-line option regarding efficacy and tolerability in areas where standard therapy is inaccessible.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"16 12","pages":"4675-4684"},"PeriodicalIF":2.5,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577364/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic prediction models for postoperative patients with stage I to III colorectal cancer based on machine learning.","authors":"Xiao-Lin Ji, Shuo Xu, Xiao-Yu Li, Jin-Huan Xu, Rong-Shuang Han, Ying-Jie Guo, Li-Ping Duan, Zi-Bin Tian","doi":"10.4251/wjgo.v16.i12.4597","DOIUrl":"10.4251/wjgo.v16.i12.4597","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is characterized by high heterogeneity, aggressiveness, and high morbidity and mortality rates. With machine learning (ML) algorithms, patient, tumor, and treatment features can be used to develop and validate models for predicting survival. In addition, important variables can be screened and different applications can be provided that could serve as vital references when making clinical decisions and potentially improving patient outcomes in clinical settings.</p><p><strong>Aim: </strong>To construct prognostic prediction models and screen important variables for patients with stage I to III CRC.</p><p><strong>Methods: </strong>More than 1000 postoperative CRC patients were grouped according to survival time (with cutoff values of 3 years and 5 years) and assigned to training and testing cohorts (7:3). For each 3-category survival time, predictions were made by 4 ML algorithms (all-variable and important variable-only datasets), each of which was validated <i>via</i> 5-fold cross-validation and bootstrap validation. Important variables were screened with multivariable regression methods. Model performance was evaluated and compared before and after variable screening with the area under the curve (AUC). SHapley Additive exPlanations (SHAP) further demonstrated the impact of important variables on model decision-making. Nomograms were constructed for practical model application.</p><p><strong>Results: </strong>Our ML models performed well; the model performance before and after important parameter identification was consistent, and variable screening was effective. The highest pre- and postscreening model AUCs 95% confidence intervals in the testing set were 0.87 (0.81-0.92) and 0.89 (0.84-0.93) for overall survival, 0.75 (0.69-0.82) and 0.73 (0.64-0.81) for disease-free survival, 0.95 (0.88-1.00) and 0.88 (0.75-0.97) for recurrence-free survival, and 0.76 (0.47-0.95) and 0.80 (0.53-0.94) for distant metastasis-free survival. Repeated cross-validation and bootstrap validation were performed in both the training and testing datasets. The SHAP values of the important variables were consistent with the clinicopathological characteristics of patients with tumors. The nomograms were created.</p><p><strong>Conclusion: </strong>We constructed a comprehensive, high-accuracy, important variable-based ML architecture for predicting the 3-category survival times. This architecture could serve as a vital reference for managing CRC patients.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"16 12","pages":"4597-4613"},"PeriodicalIF":2.5,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timely identification and treatment of uterine artery pseudoaneurysm after hysteroscopic procedures.","authors":"Haewon Byeon","doi":"10.4251/wjgo.v16.i12.4762","DOIUrl":"10.4251/wjgo.v16.i12.4762","url":null,"abstract":"<p><p>Uterine artery pseudoaneurysm (UAP) is a rare but potentially life-threatening complication that can occur following hysteroscopic surgery for endometrial polyp resection. This article discusses the case study by Kakinuma <i>et al</i>, which highlights the successful diagnosis and treatment of UAP in a 48-year-old primiparous woman. Utilizing advanced imaging techniques such as ultrasound and computed tomography (CT), the medical team was able to promptly identify the UAP and subsequently perform a uterine artery embolization to treat the condition. The study underscores the critical need for rapid diagnosis and intervention to prevent severe outcomes and provides practical clinical recommendations for managing similar cases. This article aims to expand on the study's findings, discuss the clinical implications, and suggest future research directions to optimize the management of UAP post-hysteroscopic surgery.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"16 12","pages":"4762-4765"},"PeriodicalIF":2.5,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142830021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}